Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01263899 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
A Phase 2 study, sponsored by S*BIO.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT01263899 is a Phase 2 study that has completed, run by S*BIO. The registered enrollment target is 28 participants.
The verdict
NCT01263899, a Phase 2 study, has completed, sponsored by S*BIO.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is a Phase 2 study to assess the efficacy of SB1518 in the treatment of patients with advanced lymphoid malignancies including Hodgkin Lymphoma, Mantle Cell Lymphoma and Indolent Lymphoma (follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma and small lymphocytic lymphoma).
Interventions
- DRUG SB1518
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01263899
The ClinicalTrials.gov registry entry for NCT01263899 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is S*BIO, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SB1518 is the first listed.
NCT01263899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01263899 about?
NCT01263899 is a clinical study titled "A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies". This is a Phase 2 study to assess the efficacy of SB1518 in the treatment of patients with advanced lymphoid malignancies including Hodgkin Lymphoma, Mantle Cell Lymphoma and Indolent Lymphoma (follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma and small lymphocytic lymphoma).
What is the current status of trial NCT01263899?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2010-12. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01263899?
The interventions under investigation include: SB1518 (DRUG).
Who is sponsoring clinical trial NCT01263899?
This trial is sponsored by S*BIO, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.